Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) traded down 9.1% during mid-day trading on Monday . The company traded as low as $0.45 and last traded at $0.45. 100 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 1,185 shares. The stock had previously closed at $0.4950.
Orgenesis Stock Performance
The stock has a market cap of $1.65 million, a price-to-earnings ratio of -0.03 and a beta of 2.89. The company has a 50 day moving average of $0.38 and a 200-day moving average of $0.37.
Orgenesis Company Profile
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
Recommended Stories
- Five stocks we like better than Orgenesis
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.jpg){kind=logo}
